What Analysts Are Saying About Apellis Pharmaceuticals Stock
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Apellis Pharmaceuticals (NASDAQ:APLS) over the past three months, with a recent average price target of $76.5. The company's financials show strong revenue growth but challenges in profitability and asset utilization.
June 28, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have mixed ratings for Apellis Pharmaceuticals, with a recent average price target of $76.5. The company's financials show strong revenue growth but challenges in profitability and asset utilization.
The mixed analyst ratings and the slight decrease in the average price target suggest a neutral short-term impact on the stock price. While the company shows strong revenue growth, its profitability and asset utilization challenges may offset positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100